Upadacitinib Beats Dupilumab in Head-to-Head Atopic Dermatitis Study

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and a Worst Pruritus Numerical Rating Scale of 0 or 1.

Related Keywords

,Eczema Area ,Severity Index ,Worst Pruritus Numerical Rating Scale ,